Product Details
| Product Name:
BRD3308 |
CAS No.:
1550053-02-5 |
| Purity:
97% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | BRD3308 |
| Description | BRD3308 is a highly selective inhibitor of HDAC3(IC50 of 54 nM), attenuating PE-mediated phosphorylation of ERK but not JNK. |
| Animal Research | Male Zucker Diabetic Fatty (Obese) rats (6-week-old); 5 mg/kg; Intraperitoneal injection; every second day |
| In vivo | BRD3308 is a selective HDAC3 inhibitor,to reduce hyperglycaemia and increase insulin secretion in a rat model of type 2 diabetes.?At diabetes onset, an ambulatory hyperglycaemic clamp was performed.?HDAC3 inhibition improved hyperglycaemia over the study period without affecting weight gain.?At the end of the hyperglycaemic clamp, circulating insulin levels were significantly higher in BRD3308-treated rats.?Pancreatic insulin staining and contents were also significantly higher.?These findings highlight HDAC3 as a key therapeutic target for β-cell protection in type 2 diabetes[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 52 mg/mL (181 mM)
|
| Keywords | β-cells | glucolipotoxicity | inflammatory | Human immunodeficiency virus | Histone deacetylases | HDAC3 | diabetes | HDAC | HIV-1 | Inhibitor | Apoptosis | latency | BRD 3308 | BRD3308 | cytokines | hyperglycaemia | HIV | inhibit | insulin | BRD-3308 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Metronidazole | Tributyrin | Curcumin | Decanedioic acid |
| Related Compound Libraries | Highly Selective Inhibitor Library | DNA Damage & Repair Compound Library | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2729996-45-4
$58.00 / 1mg
-
CAS:141517-21-7
$30.00 / 50mg
-
CAS:50874-07-2
$33.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States